Click on our social media addresses to see news from Menarini Turkey.
FLORENCE, July 6th, 2023 – Yesterday evening, the grand finale of the XXVII edition of the Menarini International Fair Play Awards was warmly greeted by over one thousand spectators at the Roman Theatre in Fiesole. The event, organised by the Menarini Fair Play Foundation and focused on the culture of fair play and respect in sport, drew to a close for the first time on this magnificent stage.
FLORENCE, Italy, 14th May 2023 -- Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of beauty. With his “Venuses,” he unknowingly established a canon of perfection that closely reflects that of modern day.
FLORENCE, Italy and NEW YORK, NY, August 19, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, today announced that EMA has validated the Marketing Authorization Application (MAA) for elacestrant, a selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. Validation of the application confirms the submission is complete and begins EMA’s centralized review procedure.
FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.
PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.
Menarini Group operates in 140 countries around the world.
Read More »